NOT-FD-21-007: Notice to Extend the Application Due Date for RFA-FD-21-014 - "Development of Methods to Evaluate the Impact of Design Differences to the User Interface of Generic Drug-Device Combination Products in Comparison to their Reference Listed Drugs (U01)"

Notice to Extend the Application Due Date for RFA-FD-21-014 - "Development of Methods to Evaluate the Impact of Design Differences to the User Interface of Generic Drug-Device Combination Products in Comparison to their Reference Listed Drugs (U01)"

Notice Number:

NOT-FD-21-007

Key Dates

Release Date:

February 8, 2021

Related Announcements

RFA-FD-21-014 - Development of Methods to Evaluate the Impact of Design Differences to the User Interface of Generic Drug-Device Combination Products in Comparison to their Reference Listed Drugs (U01) Clinical Trials Optional

Issued by

U.S. Food and Drug Administration (FDA)

Purpose

This notice is to extend the Application Due Date for RFA-FD-21-014 - "Development of Methods to Evaluate the Impact of Design Differences to the User Interface of Generic Drug-Device Combination Products in Comparison to their Reference Listed Drugs (U01)Clinical Trials Optional"

New Application Due Date(s)

March 25, 2021, by 11:59 PM Eastern Time

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the applications during the submission process by the due date.

Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.

Late applications will not be acceptable for this FOA.

Inquiries

Please direct all inquiries to:

Shashi Malhotra

Grants Management Specialist

Office if Acqusitions and Grants Services

Tel: 240-402-7592

Email: Shashi.Malhotra@fda.hhs.gov